Lupin partners ERN for Luforbec launch in Spain

Lupin Limited has announced a strategic collaboration with LABORATORIOS ERN S.A. (ERN) to launch Luforbec® (beclometasone/formoterol) pMDI in Spain. This fixed-dose combination is indicated for adult asthma and COPD treatment. The partnership leverages Lupin's respiratory expertise and manufacturing capabilities with ERN's established Spanish market presence. This move signifies Lupin's commitment to expanding access to quality respiratory care in Spain, following successful launches in the UK and Germany.